All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
FMC63 is a CD19-specific IgG1 mouse monoclonal antibody, which is a target for immunotherapy of B-lineage leukemia and lymphoma. FMC63 scFv is the most commonly used extracellular domain component of CD19-specific CARs. So far, most of the reported CART-CD19 clinical trials contain anti-CD19 scFv derived from FMC63, such as the two FDA-approved CARs Kymriah and Yescarta. This product was verified to specifically recognize the antigen recognition domain of FMC63-derived CAR.
There are currently no customer reviews or questions for Anti-FMC63 scFv Monoclonal Antibody, Unconjugated (CAR-AB-ZP3). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION